These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26172319)

  • 21. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
    Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
    Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson's disease.
    Kwon IH; Choi HS; Shin KS; Lee BK; Lee CK; Hwang BY; Lim SC; Lee MK
    Neurosci Lett; 2010 Dec; 486(1):29-33. PubMed ID: 20851167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway.
    Meshul CK; Cogen JP; Cheng HW; Moore C; Krentz L; McNeill TH
    Exp Neurol; 2000 Sep; 165(1):191-206. PubMed ID: 10964498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
    Lin L; Yan M; Wu B; Lin R; Zheng Z
    Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
    Haddadi R; Mohajjel Nayebi A; Brooshghalan SE
    Neurosci Lett; 2013 Oct; 555():106-11. PubMed ID: 24045063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired glutamatergic projection from the motor cortex to the subthalamic nucleus in 6-hydroxydopamine-lesioned hemi-parkinsonian rats.
    Wang YY; Wang Y; Jiang HF; Liu JH; Jia J; Wang K; Zhao F; Luo MH; Luo MM; Wang XM
    Exp Neurol; 2018 Feb; 300():135-148. PubMed ID: 29126889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
    Penttinen AM; Suleymanova I; Albert K; Anttila J; Voutilainen MH; Airavaara M
    J Neurosci Res; 2016 Apr; 94(4):318-28. PubMed ID: 26762168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
    Maccarrone M; Gubellini P; Bari M; Picconi B; Battista N; Centonze D; Bernardi G; Finazzi-Agrò A; Calabresi P
    J Neurochem; 2003 May; 85(4):1018-25. PubMed ID: 12716433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
    Ferraro L; O'Connor WT; Beggiato S; Tomasini MC; Fuxe K; Tanganelli S; Antonelli T
    Eur J Neurosci; 2012 Jan; 35(2):207-20. PubMed ID: 22211865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
    Lin L; Meng T; Liu T; Zheng Z
    Life Sci; 2013 Mar; 92(4-5):311-6. PubMed ID: 23333823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6-hydroxydopamine rat model.
    Soria G; Aguilar E; Tudela R; Mullol J; Planas AM; Marin C
    Eur J Neurosci; 2011 Apr; 33(8):1551-60. PubMed ID: 21410791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
    Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
    Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus.
    Aono H; Choudhury ME; Higaki H; Miyanishi K; Kigami Y; Fujita K; Akiyama JI; Takahashi H; Yano H; Kubo M; Nishikawa N; Nomoto M; Tanaka J
    Glia; 2017 Nov; 65(11):1833-1847. PubMed ID: 28836295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats.
    Matheus FC; Rial D; Real JI; Lemos C; Ben J; Guaita GO; Pita IR; Sequeira AC; Pereira FC; Walz R; Takahashi RN; Bertoglio LJ; Da Cunha C; Cunha RA; Prediger RD
    Behav Brain Res; 2016 Mar; 301():43-54. PubMed ID: 26707254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive impairment in motor skill learning at 12 and 20 weeks post 6-OHDA- SNc lesion in rats.
    Gambhir H; Mathur R; Behari M
    Parkinsonism Relat Disord; 2011 Jul; 17(6):476-8. PubMed ID: 21367640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion.
    Zuch CL; David D; Ujhelyi L; Hudson JL; Gerhardt GA; Kaplan PL; Bickford PC
    Brain Res; 2004 Jun; 1010(1-2):10-6. PubMed ID: 15126112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
    Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
    Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.